Northwestern Mutual Wealth Management Co. Reduces Holdings in Abbott Laboratories $ABT

Northwestern Mutual Wealth Management Co. cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 265,706 shares of the healthcare product maker’s stock after selling 9,094 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Abbott Laboratories were worth $33,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the period. Capital International Investors raised its position in Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after purchasing an additional 1,478,076 shares during the last quarter. Invesco Ltd. raised its position in Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Ameriprise Financial Inc. raised its position in Abbott Laboratories by 3.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after purchasing an additional 499,351 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Abbott Laboratories by 7.2% during the 3rd quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock valued at $1,727,869,000 after purchasing an additional 864,531 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock worth $353,097 over the last 90 days. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 1.1%

ABT opened at $85.36 on Friday. The stock has a market cap of $148.68 billion, a PE ratio of 23.91, a PEG ratio of 1.43 and a beta of 0.65. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The business has a 50 day moving average of $94.46 and a 200-day moving average of $110.69. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on ABT. Raymond James Financial lowered their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Piper Sandler cut their price target on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Mizuho cut their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, BTIG Research reiterated a “buy” rating and issued a $131.00 price target on shares of Abbott Laboratories in a report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $119.09.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.